Placeholder Banner

BIO Welcomes John Delacourt as Deputy General Counsel

March 15, 2023
Media Contact
Karen Batra

Mr. Delacourt is a senior litigator and regulatory counselor with more than a decade of experience advising biotech companies

WASHINGTON – (March 15, 2023) – The Biotechnology Innovation Organization (BIO) welcomes John Delacourt as Deputy General Counsel – VP Health, Regulatory, and Commercial Operations. John will work with BIO’s staff to lead legal support for commercial operations and with its membership to ensure patient access to life-saving medicines, bring down barriers to innovation, and promote policies conducive to advances in agriculture and environmental science.

 John comes to BIO from another biotech trade group – the Plasma Protein Therapeutics Association (PPTA) – where he served as Chief Legal Officer & Head of Global Policy. While at PPTA, John led the association’s litigation defense and regulatory compliance efforts in both the United States and Europe. He also served as legal advisor to PPTA’s principal governing bodies, including on such issues as drug shortage preparedness, discriminatory labeling practices, and secure handling of biometric data.

Prior to joining PPTA, John practiced at major law firms in Washington, D.C. and New York. He also served in senior roles at the Federal Trade Commission, including as Chief Antitrust Counsel of the FTC’s Office of Policy Planning.

“John’s healthcare and compliance experience make him a welcome addition to our growing legal team,” said Chief Legal Officer Peter McHugh. “As BIO continues to address the legal challenges presented by the Inflation Reduction Act, advocate for efficient market access for innovative products, and support a favorable environment for biotech investment, we are excited to have John on our side.”

John is a graduate of Georgetown University and Harvard Law School.

Discover More
Healthcare Ready, Biotechnology Innovation Organization, and Wakefield Research release data  Washington (March 30, 2023) -- The last several years have shown that preparing for a public health emergency is vital to protect the public, our…
Biotechnology companies are hard at work on the cutting-edge innovations we need, but those breakthroughs are at risk from current tax policy. The Biotechnology Innovation Organization, which represents more than 1,000 biotech companies, thanks…
"The ecosystem that allows America to develop groundbreaking new medicines is extremely important to our nation and to patients who depend on biotechnology companies. The recent actions by the FDIC, the Federal Reserve, and Treasury to allow SVB…